ProQR Therapeutics N.V. (PRQR): Sotuvning operatsion marjasi

ProQR (PRQR) - korporativ logo

ProQR Therapeutics N.V. (PRQR) GURU.Markets tahlillari tomonidan kuzatiladigan choraklik operatsion marjaga ta'sir ko'rsatgan holda, dori portfelini optimallashtirish uchun moslashuvchan boshqaruvdan foydalanmoqda. -234.10 qiymati parametrning joriy holatini belgilaydi. Axiomer RNA tahrirlash segmentidagi kuchli narx belgilash imkoniyati va sinovlarning tashqi CRO larga samarali topshirilishi biznesning fundamental barqarorligini ta'minlab, innovatsion dori vositalarini ishlab chiqish davrida operatsion risklarni minimallashtiradi.

PRQR - ProQR Operatsion foyda koeffitsiyenti 04.07.2022 - 19.11.2026 oraligʻida

ProQR Therapeutics N.V. kompaniyasining tahliliy kesimlari

- aksiya narxi va baholash bo'yicha konsensus prognoz:
- birja kapitallashuvi ma'lumotlari:
Kompaniyaning dastlabki tahlili:ProQR
ProQR tayyor mahsulotlari

ProQR Therapeutics N.V. (PRQR) investorlari RNA tahrirlash sektoridagi intellektual mulkni monetizatsiya qilish samaradorligini baholashlari kerak. Ushbu ko'rsatkich qarz yuklamasi va soliqlar ta'sirini hisobga olmagan holda, umumiy tushumda operatsion foydaning ulushini belgilaydi. Operatsion foyda marjasini tahlil qilish orqali Axiomer platformasining kengayish imkoniyatlarini baholash mumkin. Eli Lilly dan kelayotgan litsenziyalash to'lovlari kapital xarajatlarni minimallashtirib, marjalarni bevosita oshiradi. Ushbu metrikaning barqaror o'sishi kapital talab qiladigan ishlab chiqarishdan qochadigan biznes modelining barqarorligini tasdiqlaydi.

ProQR Therapeutics N.V. raqobatchilari tahlili

Sotuvning operatsion marjasi TEM|QGEN - Operatsion foyda bo'yicha marjinallik|Operatsion marja IONS|RGEN - Sotuvning operatsion rentabelligi|Operatsion rentabellik Avidity RNA|Operatsion marja CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operatsion marja|Ultragenyx Pharma (RARE) - Sotuvning operatsion marjasi|beamtx.com (BEAM) - Operatsion rentabellik|SRPT: Operatsion foyda koeffitsiyenti|Sotuvning operatsion marjasi TWST|TXG - Operatsion foyda bo'yicha marjinallik|Operatsion marja NTLA|Operatsion faoliyat rentabelligi Stoke Therapeutics|Operatsion rentabellik BioLife Solutions BLFS|Wave Life Sciences (WVE) - Sotuvning operatsion rentabelligi|Maze Therapeutics, Inc. - Operatsion marja|Operatsion faoliyat rentabelligi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operatsion rentabellik|TSHA: Operatsion foyda koeffitsiyenti|Operatsion rentabellik uniQure Pharma|MGTX - Operatsion foyda bo'yicha marjinallik|Operatsion marja RGNX|Operatsion rentabellik SLDB (Solid Biosciences)|Ocugen Corp - Sotuvning operatsion marjasi|PACB: Operatsion foyda bo'yicha sotuv rentabelligi|benitec.com - Operatsion marja|DSGN - Operatsion marja|RCKT: Operatsion marja|FDMT (4D Molecular Therapeutics Inc) - Operatsion rentabellik|Sotuvning operatsion marjasi LXEO|Operatsion rentabellik KRRO|Operatsion marja EDIT|SLN - Sotuvning operatsion rentabelligi|Operatsion marja CDXS (Codexis, Inc.)|SGMO: Operatsion foyda bo'yicha sotuv rentabelligi|Nautilus Biotechnology - Operatsion marja|Operatsion foyda normasi MGX (Metagenomi, Inc)|DTIL: Operatsion marja|GBIO: Operatsion foyda koeffitsiyenti|Operatsion rentabellik Boundless Bio Inc.|Sotuvning operatsion marjasi Exicure (XCUR)|Operatsion marja IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operatsion foyda normasi|Mustang Bio, Inc. - Sotuvning operatsion marjasi|RNAZ - Sotuvning operatsion marjasi|BNGO: Sotuvning operatsion marjasi|APDN (Applied DNA Sciences Inc) - Operatsion foyda bo'yicha sotuv rentabelligi|BLUE (Bluebird Bio) - Sotuvning operatsion marjasi|ImmunoPrecise Antibodies Ltd - Operatsion foyda normasi|OMGA (Omega Therapeutics Inc) - Operatsion marja|Operatsion rentabellik OMIC|Operatsion rentabellik Regulus Therapeutics Inc. (RGLS)|Sotuvning operatsion marjasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Sotuvning operatsion marjasi|Operatsion foyda normasi TCON|UBX - Operatsion rentabellik